Full-Time

Sr Scientist

Vaccine Technologies

Posted on 1/15/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops medicines for serious diseases

Biotechnology
Healthcare

Compensation Overview

$108.3k - $176.7kAnnually

Senior, Expert

Tarrytown, NY, USA

Category
Lab & Research
Medical Research
Required Skills
Data Analysis
Requirements
  • PhD with 2+ years postdoctoral or industrial experience, or MS with 5+ years, or BS with 8+ years of experience in immunology, vaccine research, cancer biology, or related field
  • Highly skilled in flow cytometry
  • >5 years experience in developing primary human and murine cell-based in vitro/ex vivo functional assays
Responsibilities
  • Develop strategies to screen and triage novel vaccine candidates
  • Independently develop and execute primary human and murine immune cell functional assays, including co-culture assays of immune cells and tumor cells
  • Independently design multicolor flow cytometry panels to characterize human PBMCs and other human samples; operate high-parameter flow cytometers and perform analysis
  • Perform high-throughput T cell screening to determine antigen-TCR pairing
  • In vitro cell engineering, characterization and functional assays, such as TCR engineering
  • Lead sample requisition from commercial sources and manage inventory of critical reagents
  • Perform data analysis, troubleshoot experiments, and record results in electronic notebook
  • Collaborate with multiple teams to achieve shared project goals
Desired Qualifications
  • Excited to develop novel primary cell assay technologies and learn new techniques to evaluate vaccines
  • Strong communication and presentation skills
  • Interest in participating in exciting cross-functional projects that involve multiple teams
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and licensing its technologies. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring that its products meet high safety and efficacy standards.

Company Stage

IPO

Total Funding

$684M

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's investment in Truveta enhances its genomic data capabilities for personalized medicine.
  • The Oxular acquisition expands Regeneron's portfolio in retinal disorder treatments.
  • Dupixent's FDA review for CSU could open a new revenue stream for Regeneron.

What critics are saying

  • Class action lawsuits may lead to financial liabilities and reputational damage.
  • Investment in Truveta may not yield expected financial returns.
  • Competition from AstraZeneca and Amgen could impact Regeneron's market share.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative treatments in serious diseases.
  • The company collaborates with academic and research institutions to enhance R&D efforts.
  • Regeneron's strategic partnerships enable shared costs and profits in new treatment development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours